Singapore, May 27 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the pos... Read More
Singapore, May 27 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507)... Read More
U.S., May 27 -- ClinicalTrials.gov registry received information related to the study (NCT07606482) titled 'Comparative Study of Fishtail Versus Waisted Teardrop Closure Techniques in Mastectomy Patie... Read More
U.S., May 27 -- ClinicalTrials.gov registry received information related to the study (NCT07607509) titled 'Lumbar Paravertebral Block vs Erector Spinae Plane Block in Elderly Patients Undergoing Lumb... Read More
Singapore, May 27 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherap... Read More
U.S., May 27 -- ClinicalTrials.gov registry received information related to the study (NCT07606911) titled 'The Effect of Liposomal Bupivacaine on Rebound Pain After Peripheral Nerve Block.' on May 19... Read More
Singapore, May 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety... Read More
Singapore, May 27 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Mo... Read More
U.S., May 27 -- ClinicalTrials.gov registry received information related to the study (NCT07605611) titled 'Somatostatin Plus Clear Liquid Diet Versus Diverting Stoma in Patients With Rectal Cancer Un... Read More
Singapore, May 27 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in... Read More